Fortress Biotech Inc (NASDAQ:FBIO) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 16, 2016
Zacks Investment Research has downgraded Fortress Biotech Inc (NASDAQ:FBIO) to Hold in a statement released on 10/11/2016.
On 10/03/2016, Roth Capital released a statement about Fortress Biotech Inc (NASDAQ:FBIO) upped the target price from $0.00 to $9.00 that suggested an upside of 2.03%.
Having a price of $2.82, Fortress Biotech Inc (NASDAQ:FBIO) traded -2.59% lower on the day. With the last stock price down -11.18% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. FBIO has recorded a 50-day average of $2.77 and a two hundred day average of $2.96. Trade Volume was down over the average, with 45,276 shares of FBIO changing hands under the typical 87,331
Recent Performance Chart
Fortress Biotech Inc has with a one year low of $2.10 and a one year high of $4.66 and has a market capitalization of $0.
General Company Details For Fortress Biotech Inc (NASDAQ:FBIO)
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.